PROC - Procaps Group, S.A.
Previous close
2.49
0 0%
Share volume: 300
Last Updated: Thu 26 Dec 2024 08:10:17 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
1.30%
PREVIOUS CLOSE
CHG
CHG%
$2.49
0.00
0.00%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
-6.06%
1 Month
82.35%
3 Months
14.81%
6 Months
-1.20%
1 Year
-37.69%
2 Year
-53.90%
Key data
Stock price
$2.49
DAY RANGE
$2.49 - $2.52
52 WEEK RANGE
$0.60 - $4.95
52 WEEK CHANGE
-$40.10
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Ruben Minski
Region: US
Website: procapsgroup.com
Employees: 4,900
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: procapsgroup.com
Employees: 4,900
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Procaps Group, S.A. operates as an integrated healthcare and pharmaceutical company worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas. It also provides drugs for hospital use, such as antibiotic, blood clot, personal protective equipment, immunosuppressant, oncology, and analgesics products.
Recent news